An angiotensin peptide for use in treating epidermolysis bullosa, wherein the treatment comprises administering the peptide to a subject suffering from an epidermolysis bullosa, wherein the angiotensin peptide is selected among the following peptides: a) the naturally-occurring Angiotensin amino acid sequence of Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 (SEQ ID NO: 1); b) is a linear peptide and has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 2); c) is a linear peptide and has the amino acid sequence of Ala 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 3); d) is a linear peptide and has the amino acid sequence of Asp 1 -Arg 2 -Nle 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 (SEQ ID NO: 6); e) is a linear peptide and has the amino acid sequence of Ala 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 (SEQ ID NO: 23); f) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 2) and comprises a linkage between Ser 4 and Cys 7; g) is a cyclic peptide, has the amino acid sequence of Ala 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 3) and comprises a linkage between Ser 4 and Cys 7; h) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Abu 4 -Ile 5 -His 6 -Ala 7 (SEQ ID NO: 15) and comprises a thioether bridge between Ser 4 and Cys 7; i) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Ala 4 -Ile 5 -His 6 -Abu 7 (SEQ ID NO: 16) and comprises a thioether bridge between Ser 4 and Cys 7; j) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Nle 3 -Abu 4 -Ile 5 -His 6 -Ala 7 (SEQ ID NO: 18) and comprises a thioether bridge between Ser 4 and Cys 7; or k) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Nle 3 -Ala 4 -Ile 5 -His 6 -Abu 7 (SEQ ID NO: 19) and comprises a thioether bridge between Ser 4 and Cys 7. a) the naturally-occurring Angiotensin amino acid sequence of Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 (SEQ ID NO: 1); b) is a linear peptide and has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 2); c) is a linear peptide and has the amino acid sequence of Ala 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 3); d) is a linear peptide and has the amino acid sequence of Asp 1 -Arg 2 -Nle 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 (SEQ ID NO: 6); e) is a linear peptide and has the amino acid sequence of Ala 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7 (SEQ ID NO: 23); f) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 2) and comprises a linkage between Ser 4 and Cys 7; g) is a cyclic peptide, has the amino acid sequence of Ala 1 -Arg 2 -Val 3 -Ser 4 -Ile 5 -His 6 -Cys 7 (SEQ ID NO: 3) and comprises a linkage between Ser 4 and Cys 7; h) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Abu 4 -Ile 5 -His 6 -Ala 7 (SEQ ID NO: 15) and comprises a thioether bridge between Ser 4 and Cys 7; i) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Val 3 -Ala 4 -Ile 5 -His 6 -Abu 7 (SEQ ID NO: 16) and comprises a thioether bridge between Ser 4 and Cys 7; j) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Nle 3 -Abu 4 -Ile 5 -His 6 -Ala 7 (SEQ ID NO: 18) and comprises a thioether bridge between Ser 4 and Cys 7; or k) is a cyclic peptide, has the amino acid sequence of Asp 1 -Arg 2 -Nle 3 -Ala 4 -Ile 5 -His 6 -Abu 7 (SEQ ID NO: 19) and comprises a thioether bridge between Ser 4 and Cys 7.